Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1838]

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast...

Dr Zahi Mitri - OHSU Hospital, Portland, USA

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer ( Dr Zahi Mitri - OHSU Hospital, Portland, USA )

Better education about breast cancer treatment in Africa

Dr Beatrice Wiafe-Addai - Peace And Love Hospital Breast care International...

Better education about breast cancer treatment in Africa ( Dr Beatrice Wiafe-Addai - Peace And Love Hospital Breast care International, Accra, Ghana )

Genomic trends across the African Diaspora for breast cancer

Prof Melissa B Davis - Weill Cornell Medical College, New York, USA

Genomic trends across the African Diaspora for breast cancer ( Prof Melissa B Davis - Weill Cornell Medical College, New York, USA )

Highlights from ASCO 2019

Asst. Prof Bishal Gyawali and Monique Biryiana

Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )

Potential of PARP inhibitors for metastatic breast cancer

Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA

Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )

PARP inhibitors are a promising alternative to chemotherapy for patients with...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival...

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Ribociclib and endocrine therapy improves survival for pre-menopausal women...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Treating ovarian cancer patients with PARP inhibitors

Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA

Treating ovarian cancer patients with PARP inhibitors ( Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA )

PARP inhibitors and their side effects in solid tumour therapy

Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA

PARP inhibitors and their side effects in solid tumour therapy ( Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA )

Benefits and challenges of using PARP inhibitors to treat metastatic breast...

Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA

Benefits and challenges of using PARP inhibitors to treat metastatic breast cancer ( Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA )

More from ecancer